It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty).
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).